MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer

This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy. The primary objective is to evaluate whether a personalized follow-up and adjuvant treatment strategy-based on the combination of ctDNA-based minimal residual disease (MRD) testing and pathological response-can effectively improve the 2-year postoperative recurrence-free survival (RFS). The study will enroll 100 patients scheduled for radical surgery who have undergone neoadjuvant immunotherapy (in combination with platinum-

Trial Details

NCT ID
NCT07894458
Phase
NA
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Signed written informed consent.
  • Male or female, aged ≥ 18 and \< 85 years.
  • Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.
  • Tumor tissue and blood samples obtainable at all protocol-specified time-points.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →